Application
Fig1: Western blot analysis of IGLC2 on human IGLC2 recombinant protein using anti-IGLC2 antibody at 1/1,000 dilution.Application
Fig2: Western blot analysis of IGLC2 on HEK293 (1) and IGLC2-hIgGFc transfected HEK293 (2) cell lysate using anti-IGLC2 antibody at 1/1,000 dilution.Application
Fig3: Immunohistochemical analysis of paraffin-embedded human colon tissues using anti-IGLC2 antibody. Counter stained with hematoxylin.Application
Fig4: Immunohistochemical analysis of paraffin-embedded human endometrial cancer tissue using anti-IGLC2 antibody. Counter stained with hematoxylin.| Product Name | IGLC2 [E12-B9] |
|---|---|
| Antibody Type | Primary Antibodies |
| Antigen Alias | Ig lambda chain C regions antibody IGLC antibody immunoglobulin lambda constant region 2 (Kern- Oz- marker) antibody MGC20392 antibody MGC45681 antibody partial Ke Oz polypeptide antibody |
| Product description | Constant region of immunoglobulin heavy chains. Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens . The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen . |
| Immunogen | Recombinant protein |
| Clonality | Monoclonal |
|---|---|
| Isotype | IgG1 |
| Host Species | Mouse |
| Tested Applications | WBIHC |
| WB:1:500 IHC:1:50-1:200 |
|
| Species Reactivity | Human |
| Concentration | 2mg/ml |
| Alternative Names | Ig lambda chain C regions antibody IGLC antibody immunoglobulin lambda constant region 2 (Kern- Oz- marker) antibody MGC20392 antibody MGC45681 antibody partial Ke Oz polypeptide antibody |
|---|---|
| Molecular Weight(MW) | 11 kDa |
| Cellular Localization | Secreted, Cell membrane. |
| SwissProt ID | P0DOY2 |
|---|
Application
Fig1: Western blot analysis of IGLC2 on human IGLC2 recombinant protein using anti-IGLC2 antibody at 1/1,000 dilution.
Application
Fig2: Western blot analysis of IGLC2 on HEK293 (1) and IGLC2-hIgGFc transfected HEK293 (2) cell lysate using anti-IGLC2 antibody at 1/1,000 dilution.
Application
Fig3: Immunohistochemical analysis of paraffin-embedded human colon tissues using anti-IGLC2 antibody. Counter stained with hematoxylin.
Application
Fig4: Immunohistochemical analysis of paraffin-embedded human endometrial cancer tissue using anti-IGLC2 antibody. Counter stained with hematoxylin.| Positive Control | Human IGLC2 recombinant protein, IGLC2-hIgGFc transfected HEK293 cell lysate, human colon tissues, human endometrial cancer tissue. |
|---|---|
| Application Notes | WB:1:500 IHC:1:50-1:200 |
| Form | Liquid |
|---|---|
| Storage Instructions | Store at +4℃ after thawing. Aliquot store at -20℃ or -80℃. Avoid repeated freeze / thaw cycles. |
| Storage Buffer | 1*TBS (pH7.4), 1%BSA, 40%Glycerol. Preservative: 0.05% Sodium Azide. |
